Galveston, Texas 77551


The proposed study will test the hypothesis that Propranolol, fenofibrate and fenofibrate plus propranolol have therapeutic, physiological, and metabolic effects that will improve clinical outcomes, and the long-term recovery, rehabilitation, and QOL in burned patients.

Study summary:

Determine the clinical benefits and underlying mechanisms whereby the metabolic perturbators fenofibrate and propranolol impact burn patient outcomes. The investigators hypothesize that these metabolic regulators given for one year will maintain body mass, improve muscle function by increasing protein synthesis, augment wound healing, reduce fibrosis, improve cardiovascular function, reduce systemic inflammation, restore insulin sensitivity, and decrease liver dysfunction without the risk of the hypoglycemia.


Inclusion Criteria: - 0 through 80 years - ≥ 20% TBSA Burn injury Exclusion Criteria: Pregnancy History or existence of pre-burn injury conditions - Allergies to propranolol or fenofibrate - Asthma requiring treatment - Congestive heart failure (measured ejection fraction < 20%) - Renal or hepatic disease - Medical condition requiring glucocorticoid treatment - History of AIDS, ARC or HIV - History of Cancer within 5 years Decision not to treat due to burn injury severity or futility as deemed by the clinical team



Primary Contact:

Principal Investigator
David N Herndon, MD
University of Texas

Catherine Reed, RN
Phone: 409-771-6987

Backup Contact:

Deb Benjamin, RN
Phone: 409-770-6731

Location Contact:

Galveston, Texas 77551
United States

Cathy Reed, BSN
Phone: 409-770-6987

Site Status: Recruiting

Data Source:

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.